Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 1.00 |
| ▸ | TTR | P02766 | 3/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555208 | 1.00 | ENPP2 (1.00) | ENPP2TTRP4HBKDM4EALDH1A1 | |
| SCHEMBL9214261 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL9214256 | 0.82 | ENPP2 (0.69) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL788775 | 0.77 | ENPP2 (0.62) | ENPP2TTRP4HBKDM4E | |
| SCHEMBL31047371 | 0.77 | ENPP2 (0.62) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL24598773 | 0.77 | ENPP2 (0.62) | ENPP2TTRKDM4EALDH1A1MGLL | |
| SCHEMBL788776 | 0.77 | ENPP2 (0.62) | ENPP2TTRP4HBKDM4E | |
| SCHEMBL11046823 | 0.76 | ENPP2 (0.61) | ENPP2P4HBKDM4E | |
| SCHEMBL11046826 | 0.76 | ENPP2 (0.61) | ENPP2P4HBKDM4E | |
| SCHEMBL22692 | 0.76 | NFE2L2 (0.65) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ENPP2 557/4885TTR 2438/4885P4HB 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.